Liver disease accounts for approximately 2 million deaths per year worldwide with numbers rising over the last decade. The COVID-19 Pandemia will further accelerate the appearance of liver disease due to a worldwide increase of obesity and alcohol use.

Accumulated toxins due to liver failure lead to secondary organ failure & inhibit liver recovery. Many of these toxins are reversibly bound to albumin (ALB) in the blood circulation and cannot be removed by conventional dialysis treatments.

Albutec’s Hepalbin^TM adsorbents are capable of effectively removing albumin bound toxins through the dialysis membrane. Significant improvements can be demonstrated by laboratory measures including Albumin Binding Capacity (ABiC). This is the decisive change as the all new Hepalbin^TM Maxicycler has a significant impact on regeneration and survival.

Albutec has taken a disruptive approach by focusing its research and development towards improving albumin adsorbents for liver dialysis treatments. Utilizing customized charcoal adhered to specially designed discs embedded in optimal flow dynamics has led to the development of the Hepalbin^TM Maxicycler Series - Our new generation of modular adsorbents which create a uniquely effective albumin for detoxification (Albunique^TM).